Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|April 2, 2004
- Pharmaceutical Technology-04-02-2004
- Volume 28
- Issue 4
Spotlight on Business Risk
Author(s)Jim Miller
Recent events in the pharmaceutical outsourcing industry highlight the importance of ongoing attention to contractors' financial situations and their strategic intent.
Advertisement
Articles in this issue
over 22 years ago
Vibration Technology for Active Dry-Powder Inhalersover 22 years ago
In the Spotlight April 2004over 22 years ago
FDA Attacks Counterfeitsover 22 years ago
Synthetic Excipients Challenge All-Natural Organicsover 22 years ago
April 2004over 22 years ago
Controlled-Release Dosage Forms for Diltiazem HydrochlorideAdvertisement
Related to this article
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
PharmTech’s Weekly Roundup—September 25, 2026
3
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5